10-K: AngioDynamics Narrows Losses and Boosts Margins Amid Strategic Portfolio Shift

AngioDynamics, a medical technology company, reported a significant reduction in net loss and an increase in gross margin for fiscal year 2025, driven by strong growth in its Med Tech segment and strategic divestitures, despite an overall revenue decline.

Summary

• Net sales for fiscal year 2025 decreased by 3.8% to $292.5 million, down from $303.9 million in fiscal year 2024, primarily due to strategic divestitures and product line discontinuations.
• The Med Tech segment, including Auryon, thrombus management, and NanoKnife, grew by 19.0% to $126.7 million in fiscal year 2025.
• Auryon sales increased by $9.8 million, and the thrombus management platform sales increased by $10.9 million, driven by AngioVac, AlphaVac, and thrombolytic products.
• NanoKnife sales remained consistent year over year, with increased disposable sales offset by decreased capital sales.
• The Med Device segment's net sales decreased by 16.0% to $165.8 million, mainly due to the divestiture of PICCs, Midline, dialysis, and BioSentry businesses, and the discontinuation of RadioFrequency Ablation.
• Gross margin improved by 300 basis points to 53.9% in fiscal year 2025, up from 50.9% in fiscal year 2024, with total gross margin increasing by $3.0 million.
• Net loss significantly decreased by $150.4 million, from $184.3 million in fiscal year 2024 to $34.0 million in fiscal year 2025.
• Loss per share improved to $0.83 in fiscal year 2025 from $4.59 in fiscal year 2024.
• Cash used in operations improved by $18.0 million, resulting in cash used of $10.1 million in fiscal year 2025.
• The company approved a share repurchase program of up to $15.0 million on July 16, 2024, repurchasing $1.7 million in common stock during fiscal year 2025.
• Manufacturing restructuring plan is underway, expected to be completed in Q3 fiscal year 2026, with anticipated annual cost savings of $15.0 million starting in fiscal year 2027.
• The company entered into an agreement to sell its Queensbury, NY and Glens Falls, NY manufacturing facilities for $6.7 million in total net proceeds, simultaneously entering into lease agreements for these facilities.

Sentiment

Score: 6

Explanation: The company shows positive momentum in reducing net losses and improving gross margins, driven by strategic divestitures and growth in its Med Tech segment. However, it remains unprofitable and continues to use cash from operations, with ongoing significant risks from competition, litigation, and macroeconomic factors. The strategic direction is clear, but execution and sustained profitability are key challenges.

Positives

• Net loss significantly decreased by $150.4 million, indicating improved financial performance compared to the prior year.
• Gross margin increased by 300 basis points to 53.9%, demonstrating enhanced profitability on sales.
• The Med Tech segment achieved strong growth of 19.0%, driven by key products like Auryon and the thrombus management platform.
• Cash flow from operations improved by $18.0 million, reducing the cash burn from operating activities.
• NanoKnife System received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024, broadening treatment options.
• CPT Category I Codes for Irreversible Electroporation (IRE) for prostate and liver will be effective January 2026, and for the pancreas in January 2027, which could boost NanoKnife adoption and reimbursement.
• Published positive APEX-AV trial results for the AlphaVac F1885 System, supporting its safety and efficacy.
• Initiated RECOVER-AV Clinical Trial in Europe for AlphaVac and AMBITION BTK RCT and Registry for Auryon, indicating continued investment in clinical evidence.
• Strategic divestitures of lower-margin businesses (PICC, Midline, dialysis, BioSentry) are expected to transform the company into a higher-growth, higher-profitability medical technology company.
• The manufacturing restructuring plan is projected to generate $15.0 million in annual cost savings starting in fiscal year 2027, improving future profitability.
• Entered into a new $25.0 million secured revolving credit facility, providing additional liquidity with no outstanding balance as of May 31, 2025.

Negatives

• Overall net sales decreased by 3.8% to $292.5 million, primarily due to the divestiture of certain product lines.
• The company reported a net loss of $34.0 million for fiscal year 2025, continuing to operate at a loss.
• Cash flow from operations remained negative, with $10.1 million used in operations for fiscal year 2025.
• The Med Device business experienced a significant decline of 16.0% in net sales due to divestitures and discontinuations.
• The company continues to face inflationary costs on raw materials, labor shortages, freight, and other costs, negatively impacting gross margin.
• The company recorded a full valuation allowance on its U.S. net deferred tax assets, indicating uncertainty about realizing future tax benefits from carryforwards.

Risks

• Intense competition in the medical device industry, with larger competitors having greater resources, potentially leading to loss of market share and pricing pressure.
• Inability to effectively develop, acquire, or market new products and technologies, or to recover investment in these initiatives.
• Reliance on the successful completion of clinical trials, such as the Ambition BTK study, with potential for delays, negative results, or termination.
• Dependence on single and limited source suppliers, which could lead to manufacturing delays, backlogs, and increased costs if supply is interrupted.
• Risks associated with reliance on third-party manufacturers, including reduced control over quality and delivery, potential price fluctuations, and regulatory disruptions.
• Changes in trade policy, treaties, government regulations, and tariffs, particularly between the U.S. and China, could increase costs and negatively impact business.
• Heavy dependence on third-party distributors for international revenues, with risks of insufficient sales efforts, financial viability issues, or non-compliance with laws.
• Exposure to currency fluctuations, trade restrictions, and economic/political instability due to international sales.
• Inability to convince customers of product cost-effectiveness or secure adequate reimbursement from third-party payors, impacting revenue growth and profitability.
• Potential for significant product liability claims, including ongoing Port Product Claims, which could result in substantial damages and may exceed insurance coverage.
• Risks associated with product line divestitures, including failure to realize expected benefits, operational disruptions, and inability to replace lost revenue and earnings.
• Adverse impacts from international and national economic conditions, such as recession, high inflation, labor shortages, and supply chain disruptions.
• Potential for impairment charges on intangible assets and fixed assets if actual results differ from assumptions and estimates.
• Limitations on the ability to utilize net operating loss carryforwards to reduce future tax liability due to IRC Section 382.
• Vulnerability to cyber-attacks or breaches of information technology systems, potentially leading to data loss, intellectual property theft, or operational disruptions.
• New risks and challenges associated with the increasing use of Artificial Intelligence (AI) based platforms, including potential for policy violations, cybersecurity risks, and increased competition.
• Disasters at manufacturing facilities or suppliers could disrupt production for a substantial amount of time.
• Anti-takeover provisions in organizational documents and Delaware law may discourage or prevent a change of control.
• Adverse impacts from global health crises, pandemics, epidemics, or other outbreaks on business operations and financial results.
• Increased scrutiny and potential non-compliance with Environmental, Social and Governance (ESG), climate change, and other sustainability-related matters.
• Subject to a comprehensive system of federal, state, and international laws and regulations, with potential for investigations, enforcement actions, and lawsuits.
• Risk of manufacturing disruptions, product sales and profitability suffering, and FDA enforcement actions if the company or its suppliers fail to comply with the FDA's Quality System Regulation (QSR) and other post-market requirements.
• Inability to obtain and maintain marketing clearance or approval from governmental agencies, including compliance with the EU Medical Device Regulation (MDR), could limit product sales.
• Products may be subject to recalls, harming reputation and diverting resources.
• Fines, penalties, or investigations if determined to be promoting products for unapproved or off-label uses.
• Impacts from laws and regulations governing the export of products, including U.S. sanctions on certain countries.
• Stock price volatility due to unpredictable operating results and external factors, potentially leading to securities class action litigation.

Future Outlook

The company is focused on expanding treatment options and improving patient outcomes in cardiovascular disease and cancer through innovative R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. Investments in high-technology products like Auryon, Mechanical Thrombectomy, and NanoKnife are expected to provide access to larger and faster-growing markets. The manufacturing restructuring plan, expected to be completed in Q3 fiscal year 2026, is projected to generate $15.0 million in annual cost savings starting in fiscal year 2027, fundamentally changing the corporate gross margin profile. The company anticipates continued growth in sales and profitability by expanding geographically, penetrating new markets, introducing new products, and increasing international presence. The company believes its current cash on hand, combined with cash from operations and access to its new revolving credit facility, will provide sufficient liquidity for at least the next 12 months.

Management Comments

• Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance.
• Our investments in our high technology products including Auryon, Mechanical Thrombectomy (which includes AngioVac and AlphaVac) and NanoKnife, will provide us access to larger and faster growing markets.
• Throughout the year, we introduced strategic moves designed to streamline our business, improve our overall business operations and position ourselves for growth.
• The restructuring activities associated with the modified Plan are still expected to be completed in the third quarter of fiscal year 2026 and are expected to generate $15.0 million in annual cost savings starting in fiscal year 2027.
• The Company continued its disciplined product development process which is intended to improve the Company’s ability to bring new products to market and achieve clinical and regulatory pathway expansion.
• To create value and drive future growth, the Company is focused on ensuring that the sales team is appropriately trained on how to market the products to our customers and that our customers are receiving the appropriate training and exposure to our products.

Industry Context

AngioDynamics operates in the highly competitive and rapidly evolving medical technology industry, characterized by continuous technological advancements, frequent product introductions, and changing customer needs. The industry is experiencing consolidation, leading to larger companies with greater market power and increased pricing pressure. Healthcare cost containment initiatives by governments and private sectors are emphasizing cost-effective medical devices and therapies, impacting reimbursement rates. The company's strategic shift towards higher-growth Med Tech segments like peripheral arterial disease, thrombus management, and soft tissue ablation aligns with industry trends focusing on minimally invasive, image-guided procedures and specialized treatments for cardiovascular disease and cancer. However, the industry also faces challenges from global economic conditions, supply chain disruptions, labor shortages, and increasing regulatory scrutiny, including stricter FDA and international (e.g., MDR) requirements.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess AngioDynamics' performance against global benchmarks. However, it mentions key competitors such as Boston Scientific Corporation, Cook Medical, Medtronic, Merit Medical, Terumo Medical Corporation, Johnson and Johnson, Philips Healthcare, Stryker Corporation, Penumbra, Inc., Varian Medical Systems, and Abbott Laboratories, indicating a highly competitive landscape with larger, more diversified players.

Management Changes

Corporate Governance

Legal Proceedings

• The company is defending approximately 162 product liability claims involving its port products, consolidated for pretrial proceedings in the U.S. District Court for the Southern District of California, seeking damages for personal injury.
• Resolved ongoing patent infringement litigations with Becton, Dickinson and Company (BD) through a settlement agreement on March 31, 2024, involving cross-licensing of patents and payments.
• Under the settlement with BD, the company made a one-time lump sum payment of $7.0 million and will make six minimum annual payments of $2.5 million starting in fiscal year 2025, with potential additional payments based on port product sales.
• A contingent payment of $3.0 million is due to BD if the Federal Circuit reverses or vacates District Court's findings of invalidity in a specific patent case, with appellate briefing closed but no argument date set.

Stakeholder Impact

• **Shareholders:** Potential for increased value through strategic focus on high-growth segments, improved profitability, and share repurchase program. However, ongoing losses and litigation risks pose uncertainties.
• **Employees:** Impacted by manufacturing restructuring, which involves shifting some operations to third-party manufacturers and maintaining a presence in Queensbury, NY for select functions. Changes in management roles also affect personnel.
• **Customers:** Benefit from continued R&D and introduction of new and enhanced products, particularly in Med Tech. Potential for improved product availability and service through optimized manufacturing and supply chain.
• **Suppliers:** The shift to a partially outsourced manufacturing model will impact existing and new third-party suppliers, particularly those in Costa Rica, Latvia, Italy, Israel, and China.
• **Creditors:** The new $25.0 million revolving credit facility provides liquidity and demonstrates access to capital, potentially improving the company's credit profile.

Next Steps

• Complete manufacturing restructuring activities by the third quarter of fiscal year 2026, aiming for $15.0 million in annual cost savings starting fiscal year 2027.
• Continue disciplined product development and clinical/regulatory pathway expansion for new and existing products.
• Focus on training sales teams and providing appropriate product exposure and training to customers.
• Monitor and manage ongoing legal proceedings, including the Port Product Claims and the remaining contingent payment related to the BD settlement.
• Assess the level of the valuation allowance required for deferred tax assets and potentially release it if sufficient positive evidence of profitability exists in future periods.
• Manage the new $25.0 million revolving credit facility for working capital and general corporate needs.

Key Dates

Recommendation

Keywords

Medical Technology, SEC Filing, 10-K, AngioDynamics, ANGO, Med Tech, Med Device, Auryon, NanoKnife, Thrombectomy, Vascular Access, Oncology, Peripheral Artery Disease, FDA Clearance, Clinical Trials, Manufacturing Restructuring, Divestitures, Gross Margin, Net Loss, Cash Flow, Corporate Governance, Risk Factors, Intellectual Property, Product Liability, Reimbursement, Supply Chain, Cybersecurity